New diabetes clinical trial: Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Published on: August 11, 2017 at 09:30PM
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin;   Drug: Empagliflozin;   Drug: Dapagliflozin;   Drug: Dipeptidyl Peptidase-4 Inhibitor (DPP-4);   Drug: Glucagon-Like Peptide-1 Agonist (GLP-1);   Drug: Thiazolidinedione (TZD);   Drug: Sulfonylureas;   Drug: Insulin
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting – verified August 2017

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s